Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors

Award Number: F31AI200321
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 12/29/2026
PERIOD OF PERFORMANCE END DATE: 12/28/2027

Group Awards By:

View Award Description

Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors - Abstract The urgent need for new antibacterial agents is well recognized, as the rapid emergence of resistance continues to outpace current drug development efforts. To address this challenge, the Moore and Mankin/Vázquez-Laslop labs are collaborating to advance the development of translation termination inhibitors, a novel antibacterial mechanism observed only in the Class II subset of proline-rich antimicrobial peptides (PrAMPs). Apidaecin (Api) and drosocin (Dro), both Class II PrAMPs, share this unique mechanism despite having distinct sequences and binding modalities. Recently, the Mankin/Vázquez-Laslop lab identified Pdi1, an insect-derived translation termination inhibitor with similarity to Api. This proposal outlines a plan to leverage Pdi1 and the structurally distinct Dro to design and optimize novel hybrid translation termination inhibitors with enhanced potency and metabolic stability. Pdi1’s similarity to Api also provides a framework to investigate the role of secondary structure in this mechanism of action. Notably, Api’s bioactive conformation includes polyproline type II (PPII) features. Incorporating proline derivatives into Pdi1 will constrain the amide bond conformation and provide a systematic approach to study how PPII structure influences the peptide’s antimicrobial activity. The results of this work will be fundamental to the development of FDA-approvable translation termination inhibitors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $50,114 )
2026	2026	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Allergy and Infectious Diseases Research	000	1	6/30/2026	NEW	$50,114
														Subtotal = $50,114

Grand Total All Awards = $50,114

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors

Award Number: F31AI200321

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 12/29/2026

PERIOD OF PERFORMANCE END DATE: 12/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer